You are here

BeiGene

BeiGene to go solo with cancer drug after Novartis deal termination

BeiGene to go solo with cancer drug after Novartis deal termination

Yahoo/Reuters

Flag link:

Bristol Myers, BeiGene end legacy Celgene deal with settlement years after China ban

Bristol Myers, BeiGene end legacy Celgene deal with settlement years after China ban

Fierce Pharma

Bristol Myers Squibb

Flag link:

Novartis retreats from TIGIT, handing $300M candidate back to BeiGene

Novartis retreats from TIGIT, handing $300M candidate back to BeiGene

Fierce Biotech

Flag link:

AbbVie's Imbruvica-Brukinsa patent suit may have merit, and BeiGene will likely settle: expert

AbbVie's Imbruvica-Brukinsa patent suit may have merit, and BeiGene will likely settle: expert

Fierce Pharma

Flag link:

AbbVie sues BeiGene over brand-new Imbruvica patent as blood cancer rivalry heats up

AbbVie sues BeiGene over brand-new Imbruvica patent as blood cancer rivalry heats up

Fierce Pharma

Flag link:

BeiGene's gastric cancer drug succeeds in late-stage trial

BeiGene's gastric cancer drug succeeds in late-stage trial

Reuters

clinical trials

Flag link:

BeiGene Enters New Phase to Expand US Manufacturing and R&D Footprint

BeiGene Enters New Phase to Expand US Manufacturing and R&D Footprint

NJ Business

drug manufacturing

Flag link:

BeiGene pulls out of Leap of faith, letting option on immuno-oncology candidate lapse

BeiGene pulls out of Leap of faith, letting option on immuno-oncology candidate lapse

Fierce Biotech

immuno-oncology

Leap Therapeutics

Flag link:

Big Pharma regained ‘mojo’ last year, but biotech valuations remain ‘precarious’: report

Big Pharma regained ‘mojo’ last year, but biotech valuations remain ‘precarious’: report

Fierce Biotech

Moderna Therapeutics

Gilead Sciences

Flag link:

BeiGene doubles sales as Brukinsa, tislelizumab gear up for key launches

BeiGene doubles sales as Brukinsa, tislelizumab gear up for key launches

Fierce Pharma

Flag link:

This Week at FDA: Pallone pushes for greater ClinicalTrials.gov enforcement, FDA rejects Eli Lilly Alzheimer’s drug, and more

This Week at FDA: Pallone pushes for greater ClinicalTrials.gov enforcement, FDA rejects Eli Lilly Alzheimer’s drug, and more

RAPS.org

clinical trials

clinicaltrials.gov

Flag link:

BeiGene's Brukinsa wins CLL approval after topping Imbruvica in head-to-head trial

BeiGene's Brukinsa wins CLL approval after topping Imbruvica in head-to-head trial

Endpoints

Flag link:

Big caps bounce back for biopharma

Big caps bounce back for biopharma

EP Vantage

Bristol Myers Squibb

Gilead Sciences

Lantheus Holdings

Madrigal Pharmaceuticals

Moderna Therapeutics

Prometheus Biosciences

Flag link:

ASH 2022 – pirtobrutinib leads the post-Imbruvica charge

ASH 2022 – pirtobrutinib leads the post-Imbruvica charge

EP Vantage

Nurix Therapeutics

Flag link:

Go or no go? Mirati heads to the FDA

Go or no go? Mirati heads to the FDA

EP Vantage

Mirati Therapeutics

Gilead Sciences

Coherus Biosciences

TG Therapeutics

Flag link:

BeiGene heaps more pressure on AbbVie, J&J with new Brukinsa head-to-head win over Imbruvica

BeiGene heaps more pressure on AbbVie, J&J with new Brukinsa head-to-head win over Imbruvica

Fierce Pharma

Flag link:

ESMO 2022 – the new liver cancer entrants line up

ESMO 2022 – the new liver cancer entrants line up

EP Vantage

Flag link:

BeiGene and Novartis Make Late-Stage Progress against Liver Cancer

BeiGene and Novartis Make Late-Stage Progress against Liver Cancer

BioSpace

hepatocellular carcinoma

clinical trials

Flag link:

FDA Indefinitely Delays BeiGene/Novartis anti-PD-1 Esophageal Cancer Drug

FDA Indefinitely Delays BeiGene/Novartis anti-PD-1 Esophageal Cancer Drug

BioSpace

esophageal cancer

Flag link:

Pages